Condition: Intracranial Tumor · Sponsor: Dartmouth-Hitchcock Medical Center
The purposes of the research trial are to study the safety of ABY-029 and to understand how much of the drug is needed to reach brain tumors so it can be visualized best by surgeons. Investigators will do this by comparing two groups of participants that receive different, very small amounts of ABY-029. Investigators will use an imaging system during surgery to record the amount of ABY-029 in the participant's tumor and in the surrounding tissue.
This description comes directly from the study's public registry record.
Keith D Paulsen, PhD · 603-646-2695 · keith.d.paulsen@dartmouth.edu
Linton Evans, MD
Always discuss trial participation with your own doctor first.
| Dartmouth-Hitchcock Medical Center | Lebanon, New Hampshire, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07063693